Trials / Completed
CompletedNCT01874873
A Phase II Study of Anlotinib in MTC Patients
Phase 2 Study of Anlotinib in Advanced Medullary Thyroid Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 58 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Anlotibib (ALTN) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. ALTN is a kinase inhibitor of receptor tyrosine with multi-targets, especially for VEGFR2 and VEGFR3. It has the obvious resistance to new angiogenesis. The trial is to explore ALTN for the effectiveness of advanced medullary thyroid carcinoma and security.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anlotinib |
Timeline
- Start date
- 2013-04-01
- Primary completion
- 2016-12-01
- Completion
- 2016-12-01
- First posted
- 2013-06-11
- Last updated
- 2019-05-21
Locations
10 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01874873. Inclusion in this directory is not an endorsement.